Skip to content
HealthyStudy
Menu

Comparison

Oracea vs ordinary doxycycline

Oracea

DOXYCYCLINE

Approved for skin

Galderma Laboratories, L.P.Label version 23, effective 16 April 2025

Doryx MPC

DOXYCYCLINE HYCLATE

Approved for another condition

Mayne Pharma Commercial LLCLabel version 15, effective 16 February 2026

Each stripe is one section of the label, each division in a stripe one entry in that section.

Both of these are doxycycline. One is approved for the inflammatory lesions of rosacea at 40 mg, the other is an antibacterial approved for infections at higher doses. The rosacea label goes out of its way to say it should not be used as an antibiotic.

01

Side by side, straight from the labels

From the FDA label

This table is generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved.

Label sectionOraceaDOXYCYCLINEDoryx MPCDOXYCYCLINE HYCLATE
Active ingredientDoxycyclineTetracycline-class antibacterialDoxycyclineTetracycline-class antibacterial
SupplyPrescriptionPrescription
What pharmacies payAcquisition cost, not retail$29.11 per tablet, capsule or pen, brand$18.18 per tablet, capsule or pen, brand
Boxed warningNoneNone
What the FDA approved it for
  • ORACEA is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. (1. 1)
  • Limitations of Use This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. Do not use ORACEA for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease.
  • ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea.
  • DORYX MPC is a tetracycline class drug indicated for: Rickettsial Infections
  • Sexually Transmitted Infections
  • Respiratory Tract Infections
  • Specific Bacterial Infections
  • Ophthalmic Infections
  • Anthrax, Including Inhalational Anthrax (Post-Exposure)
Forms and strengths
  • 40 mg beige opaque capsule imprinted with "GLD 40" 40 mg capsule.
  • DORYX MPC (doxycycline hyclate delayed-release tablets), 60 mg are white, oval tablets containing yellow pellets and debossed with "D6" on one face and plain on the other.
  • Each tablet contains doxycycline 60 mg (equivalent to doxycycline hyclate 69.4 mg).
  • DORYX MPC Delayed-Release Tablets 60 mg
How the label says it is taken
  • Take one ORACEA capsule (40 mg) once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals.
  • Exceeding the recommended dosage may result in an increased incidence of side effects including the development of resistant microorganisms.
  • Important Dosage and Administration Instructions: DORYX MPC is not substitutable on a mg per mg basis with other oral doxycyclines.
  • Do not chew or crush tablets.
  • Dosage in Adult Patients The usual dosage of DORYX MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily.
  • In the management of more severe infections (particularly chronic infections of the urinary tract), 120 mg every 12 hours is recommended.
  • Dosage in Pediatric Patients For all pediatric patients weighing less than 45 kg with severe or life threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage of DORYX MPC is 2.6 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose.
  • For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule of DORYX MPC is 5.3 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.6 mg per kg of body weight (given as a single daily dose or divided into twice daily doses).
Most common adverse reactions
  • most common adverse reactions (incidence >2% and more common than with placebo) are nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase.
  • The following adverse reactions have been identified during post-approval use of doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Warnings and precautions
  • The use of ORACEA during tooth development (the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and reversible inhibition of bone growth.
  • Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of Clostridium difficile. If C. difficile associated diarrhea occurs, discontinue ORACEA.
  • If renal impairment exists, ORACEA doses may need to be adjusted to avoid excessive systemic accumulations of the drug and possible liver injury.
  • Photosensitivity can occur with ORACEA; Patients should minimize or avoid exposure to natural or artificial sunlight.
  • Tetracyclines have been associated with the development of autoimmune syndromes; if symptoms develop, discontinue ORACEA immediately.
  • ORACEA may cause pseudotumor cerebri (benign intracranial hypertension). Discontinue ORACEA if symptoms occur.
  • Bacterial resistance to tetracyclines may develop in patients using ORACEA. It should only be used as indicated.
  • The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown).
  • Clostridioides difficile -Associated Diarrhea. Evaluate patients if diarrhea occurs.
  • Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Limit sun exposure.
  • Overgrowth of non-susceptible organisms, including fungi, may occur. If such infections occur, discontinue use and institute appropriate therapy.
Contraindications
  • ​This drug is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the other tetracyclines.
  • ORACEA is contraindicated in persons who have shown hypersensitivity to doxycycline or other tetracyclines.
  • DORYX MPC is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.
  • Doxycycline is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.
Drug interactions
  • Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
  • Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.
  • The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
  • Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage
  • Avoid co-administration of tetracyclines with penicillin
  • Absorption of tetracyclines, including DORYX MPC is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations
  • Concurrent use of tetracyclines, including DORYX MPC may render oral contraceptives less effective
  • Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline
Label version16 April 202516 February 2026

Comparison of Oracea vs ordinary doxycycline taken from the FDA labels.

02

The dose is the difference

Written by us

Oracea is approved for the treatment of only the inflammatory lesions, the papules and pustules, of rosacea in adults. Its label states that this formulation has not been evaluated in the treatment or prevention of infections, and instructs that it not be used for treating bacterial infections or for antibacterial prophylaxis.

The higher-dose product on the other side of this table is an antibacterial with a long list of infections in its indications. Same molecule, different dose, different approval, and the labels do not overlap.

03

What Oracea does not cover

Written by us

Rosacea shows up in several ways: bumps and pimples, persistent redness, visible vessels, and eye involvement. The Oracea label states that it has not been evaluated for the redness, the visible vessels or the ocular components. It covers the lesions only.

That is a useful thing to know before expecting it to address facial redness, and it is stated in the indication rather than buried.

04

Common questions

Written by us
Is Oracea an antibiotic?
It is a tetracycline-class drug, and its label says so. It also says the formulation has not been evaluated for treating or preventing infections and should not be used for them. Both statements are in the same document.
Will it help with facial redness?
The label states it has not been evaluated for the erythematous or telangiectatic components of rosacea, which is what redness and visible vessels are called there. This page reports that limit rather than working around it.
05

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

Other comparisons in this category

Page last updated: 5 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.